Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All case investigation)

Study identifier:D9603C00001

ClinicalTrials.gov identifier:NCT05454787

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All case investigation)

Medical condition

life threatening bleeding

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

300

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 02 Jun 2022
Estimated Primary Completion Date: 31 May 2025
Estimated Study Completion Date: 31 May 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria